Anthera Pharmaceuticals (ANTH) Shares are Down -1.35%

Anthera Pharmaceuticals (ANTH) : During the past 4 weeks, traders have been relatively bearish on Anthera Pharmaceuticals (ANTH), hence the stock is down -7.45% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.84% relative to the S&P 500. The 4-week change in the price of the stock is -7.57% and the stock has fallen -1.35% in the past 1 week.

The stock has recorded a 20-day Moving Average of 5.74% and the 50-Day Moving Average is 7.48%.The 200 Day SMA reached 19.43%. Anthera Pharmaceuticals, Inc. has dropped 22.89% during the last 3-month period . Year-to-Date the stock performance stands at -36.85%.


Anthera Pharmaceuticals (NASDAQ:ANTH): After opening at $2.91, the stock dipped to an intraday low of $2.851 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $2.96 and the buying power remained strong till the end. The stock closed at $2.93 for the day, a gain of 0.69% for the day session. The total traded volume was 177,073. The stocks close on the previous trading day was $2.91.

Anthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Companys primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Companys second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.